Drug Profile
Research programme: cancer vaccines - Agenus
Alternative Names: Heat shock protein vaccine - Agenus; PhosphoSynVax™ vaccineLatest Information Update: 04 Feb 2021
Price :
$50
*
At a glance
- Originator PhosImmune
- Developer Agenus
- Class Antineoplastics; Cancer vaccines; Heat shock proteins; Immunotherapies; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Feb 2021 Preclinical development for cancer is ongoing in the US (Agenus pipeline, February 2021).
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 16 Mar 2018 Agenus has issued and pending patents for phosphorylated antigenic targets in USA